In 2023, France experienced 82 confirmed cases of Rifampicina Resistant/Multi-Drug Resistant Tuberculosis (RR-/MDR-TB). The forecast indicates a gradual rise, with an increase to 84 cases in 2024, 86 cases in 2025, 88 cases in 2026, 89 cases in 2027, and 91 cases by 2028. The year-on-year growth reveals an average annual increase of 2-3%. The compounded annual growth rate (CAGR) over the five years is approximately 2.13%.
Future trends to watch for include the impact of global public health initiatives aimed at enhancing TB control measures and the potential influence of new treatment protocols or drugs that may address drug resistance more effectively. Monitoring changes in healthcare infrastructure and policies will also be crucial in understanding and mitigating these forecasted increases.
